Pharmacogenetics, dementia prevention, and the longevity case for Pillcheck

Longevity isn't just about adding years: it's about protecting the health and quality of life that let you enjoy them. Staying active and taking the right supplements are part of the plan. But for many people, lowering the risk of heart attack, stroke, cancer and dementia also means starting the right medication, at the right dose, long before symptoms appear. These conditions remain leading causes of death, which is why prevention has to start decades earlier than most people think.

Dementia shows why. Some people inherit variants in the APOE gene that raise their risk, but a genetic predisposition does not make dementia inevitable. The 2024 Lancet Commission on dementia prevention, an international panel of experts convened by the medical journal The Lancet, identified 14 modifiable risk factors that together account for about 45% of dementia cases worldwide. Three of them, high LDL cholesterol, depression and high blood pressure, act in midlife and are treated with medication. High blood pressure and high cholesterol are also among the most common of these risk factors, and both are partly shaped by the genes you inherit.

What determines your level of risk isn't just whether you're prescribed a medication: it's whether that medication can safely and consistently control the condition over decades. How well these medications work, and how well they are tolerated, varies significantly from person to person depending on their genes. That's where pharmacogenetics (PGx) enters the longevity conversation: as a way to get ahead of the problem instead of reacting to it.

Ages 40 to 50 are when DNA-guided prescribing has the most years to pay off, because your results guide medication choices for the rest of your life. It is not the only time testing helps: a pharmacogenetic test is useful whenever you start or change a long-term medication.

The hidden gap in "modifiable" risk factors

Calling a risk factor "modifiable" assumes two things: that the treatment works as prescribed, and that you keep taking it, even on days when you feel fine. In practice, many people prescribed statins, antidepressants and blood pressure medications fall into one of three patterns: they stop the medication because of side effects; they stay on a dose that is too low because it doesn't match how their body metabolizes the drug; or they cycle through several medications trying to find one that works.

A statin can cause muscle or joint pain. Antidepressants can disrupt sleep or cause sexual side effects. Some blood pressure medications, such as amlodipine, can cause leg swelling (edema). These are often signs of a mismatch between a person's DNA and their drug or dose. It is not a willpower problem, and not a reason to give up on treatment altogether. Seen this way, pharmacogenetics is the tool that closes the gap between being prescribed a medication for a modifiable risk factor and actually controlling that risk factor, before years go by with a treatable condition left unmanaged.

Cholesterol: the biggest single lever, and the genetics behind it

Among the Lancet Commission's 14 factors, high LDL ("bad") cholesterol carries the largest weight, 7%, tied with hearing loss. The 2026 dyslipidemia guideline now recommends starting statin therapy a decade earlier, at age 30, for people with elevated cholesterol, and extends the upper age range by 5 years. That makes cholesterol the most consequential place to get treatment right from the start.

Statin pharmacogenetics gives you a head start: variants in the SLCO1B1 gene are linked to statin-associated muscle symptoms, and variants in ABCG2 and CYP2C9 change how much rosuvastatin and fluvastatin reach the bloodstream. Without that information upfront, unexplained muscle pain often leads people to stop their statin altogether, leaving LDL unmanaged for years and raising the risk of stroke and vascular dementia down the line. A pre-emptive PGx panel moves that conversation earlier: instead of adjusting a prescription after a bad reaction, your care team can choose the right statin and dose before the first one is ever written. Learn more in Are statins safe? It depends on your genetics.

Hypertension: an outsized downstream effect

High blood pressure's direct weight in the Lancet Commission's model is 2%, but its effects on the heart and blood vessels, including stroke and small vessel disease in the brain, ripple into several of the model's other factors. Its true impact on long-term brain health is larger than the number alone suggests (see How does managing your blood pressure reduce your risk of dementia?).

Pharmacogenetics shapes how you respond here too. Several classes of blood pressure medications, including some angiotensin receptor blockers (ARBs), calcium channel blockers and beta-blockers, are affected by variants in CYP2C9, CYP3A4 and CYP2D6. PGx insights can help you and your prescriber choose the right blood pressure medication and reach control sooner. If you take several medications for other conditions, a medication review by a pharmacist trained in pharmacogenetics is also highly recommended.

Arrhythmia and blood clotting: inherited risk

Stroke is less common in midlife, but when it happens it is often sudden and severe. People with undiagnosed heart rhythm problems such as atrial fibrillation, or with inherited clotting disorders (thrombophilia), are at higher risk. Screening and genetic testing can identify people at risk, such as carriers of Factor V Leiden or the prothrombin gene variant; Pillcheck reports both (the F5 and F2 genes). Quitting smoking matters for everyone at risk, and a blood thinner may be recommended when the risk is high enough, for example in atrial fibrillation.

Blood thinners also have important pharmacogenetic considerations. Warfarin is used less often today, but genotype-guided dosing helps make it a safe and effective option for prevention. Newer anticoagulants such as apixaban and rivaroxaban (DOACs) do not need gene-based dosing, but with every blood thinner, preventing clots has to be balanced against the risk of bleeding. The antiplatelet clopidogrel needs the CYP2C19 enzyme to work: about 30% of people, and more than half of people of East Asian ancestry, are intermediate or poor metabolizers and may need an alternative. Genetic testing helps identify the most suitable blood thinner and dose for your DNA.

Depression: mid-life mood, lifelong brain health

The link between depression and dementia runs both ways and depends on dose: the longer depression goes untreated or undertreated, the greater the long-term risk to brain health. The pharmacogenetics of SSRI and SNRI antidepressants, driven largely by CYP2D6 and CYP2C19 metabolizer status, shapes how well each antidepressant works, the side effects each person experiences, and how quickly remission may be achieved (see Do antidepressant medications increase the risk of dementia in older adults?).

The clinical reality today is that only about one in three people reach remission on their first antidepressant, and each unsuccessful trial leaves months of depression unmanaged. PGx-guided selection shortens that window from the outset, directly addressing a risk factor the Lancet Commission weights at 3% and protecting brain health during exactly the years when untreated depression does the most damage.

From single drugs to lifetime risk: the longevity argument

PGx isn't just about avoiding one bad reaction. It's about improving the odds of sustained risk-factor control across a 20- to 40-year midlife window. Proactive health management in your prime years means years of well-controlled cholesterol, blood pressure and mood, instead of years of trial and error.

PGx data needs a clinician who acts on it

A genetic test result without pharmacist review is a lab value, not a care decision. Healthcare providers trained in genomic medicine and pharmacists with expertise in pharmacogenetics are the ones who can interpret your DNA results and put them to work.

Pillcheck's personalized medication management model combines state-of-the-art PGx testing with expert pharmacist review to bridge the gap between genetic data and actual prescribing changes. For example, for a person taking clopidogrel, an antidepressant and a heartburn medication, a Pillcheck pharmacist guides the cardiologist, psychiatrist or family doctor in changing one or more of these medications based on the PGx results. The goal is to give recommendations that fit the patient's medication history and drug metabolism profile, and to move them off a poorly matched statin, SSRI or blood pressure medication to a suitable alternative.

Protect your brain health, starting now

• Longevity is as much a genetic medicine challenge as a lifestyle one.
• Nearly half (45%) of dementia cases could be prevented or delayed, and getting the medications right for three of the biggest culprits, cholesterol, depression and high blood pressure, is essential.
• Many insurance plan sponsors and brokers have already made pharmacogenetics part of their workplace health benefits. Ask your HR or benefits advisor whether your plan's chronic disease management includes pharmacogenetic testing, or check insurance information.
• Don't wait until health troubles start: get your PGx profile today.

Next steps

If you're a plan sponsor or broker: ask whether your benefit plan's chronic disease management includes pharmacogenetic testing. Contact us at info@pillcheck.ca.

If you're a clinician or pharmacist: explore Pillcheck's clinical resources or request a demo at info@pillcheck.ca.

If you're a patient: start your Pillcheck testing pathway today.

Frequently asked questions

How does pharmacogenetics benefit longevity?

Long-term health depends on controlling conditions such as high cholesterol, high blood pressure and depression for decades. Pharmacogenetics shows how your genes affect the medications used to treat them, so your prescriber can choose a drug and dose that are more likely to work and be tolerated from the start. That means fewer failed trials, fewer people stopping treatment because of side effects, and more years of well-controlled risk factors.

What are the modifiable risk factors for dementia?

The 2024 Lancet Commission lists 14: less education, hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, high blood pressure, obesity, excessive alcohol, social isolation, air pollution and untreated vision loss. Together they account for about 45% of dementia cases.

Can a genetic test tell me if I will get dementia?

No test can tell you for certain. Variants in genes such as APOE raise the risk, but most dementia risk comes from many factors, including the modifiable ones above. Pillcheck is a medication-response test: it does not predict dementia, but it helps you and your care team treat the risk factors you can control.

Which genes affect statins?

SLCO1B1 is the best-studied gene: variants that reduce its function raise statin levels in the blood and the risk of muscle symptoms, especially with simvastatin. ABCG2 affects rosuvastatin levels and CYP2C9 affects fluvastatin. International guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) use these genes to recommend a statin and dose.

At what age should I get a pharmacogenetic test?

Ages 40 to 50 are a good time, because many people start long-term medications for cholesterol, blood pressure or mood around then. But testing is useful at any age, especially before starting or changing a medication you may take for years.

Do I need to repeat a pharmacogenetic test?

No. Your genes do not change, so one test can guide prescribing for the rest of your life. Interpretations can be updated as new guidelines are published.

Is pharmacogenetic testing covered by insurance?

Many workplace benefit plans in Canada cover pharmacogenetic testing, often as part of chronic disease management. Check with your HR department or benefits advisor, or see our insurance information page.

Medical disclaimer: This article is for general education and is not medical advice. Do not start, stop or change any medication without talking to your physician or pharmacist.

References

Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.

Cooper-DeHoff RM et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021.

Anderson TS et al. Implications of the 2026 dyslipidemia guideline for primary prevention statin therapy. JAMA. 2026;336(7):557-564. doi:10.1001/jama.2026.11246